126 related articles for article (PubMed ID: 18852927)
1. [Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry].
Oehme L; Dörr W; Wust P; Kotzerke J
Nuklearmedizin; 2008; 47(5):205-9. PubMed ID: 18852927
[TBL] [Abstract][Full Text] [Related]
2. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.
Baechler S; Hobbs RF; Prideaux AR; Wahl RL; Sgouros G
Med Phys; 2008 Mar; 35(3):1123-34. PubMed ID: 18404947
[TBL] [Abstract][Full Text] [Related]
3. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.
Howell RW; Goddu SM; Rao DV
Med Phys; 1998 Jan; 25(1):37-42. PubMed ID: 9472824
[TBL] [Abstract][Full Text] [Related]
4. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.
Howell RW; Goddu SM; Rao DV
J Nucl Med; 1994 Nov; 35(11):1861-9. PubMed ID: 7965170
[TBL] [Abstract][Full Text] [Related]
5. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
6. A theoretical radiobiological assessment of the influence of radionuclide half-life on tumor response in targeted radiotherapy when a constant kidney toxicity is maintained.
Abou-Jaoudé W; Dale R
Cancer Biother Radiopharm; 2004 Jun; 19(3):308-21. PubMed ID: 15285877
[TBL] [Abstract][Full Text] [Related]
7. Combining the LKB NTCP model with radiosensitivity parameters to characterize toxicity of radionuclides based on a multiclonogen kidney model: a theoretical assessment.
Lin H; Jing J; Xu L; Wu D; Xu Y
Australas Phys Eng Sci Med; 2012 Jun; 35(2):165-76. PubMed ID: 22678954
[TBL] [Abstract][Full Text] [Related]
8. Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model.
Zhou C; Jones B; Moustafa M; Schwager C; Bauer J; Yang B; Cao L; Jia M; Mairani A; Chen M; Chen L; Debus J; Abdollahi A
Radiat Oncol; 2017 Nov; 12(1):172. PubMed ID: 29116014
[TBL] [Abstract][Full Text] [Related]
9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
10. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
11. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants.
Dale RG; Jones B; Coles IP
Br J Radiol; 1994 Jul; 67(799):639-45. PubMed ID: 8061998
[TBL] [Abstract][Full Text] [Related]
12. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants.
Armpilia CI; Dale RG; Coles IP; Jones B; Antipas V
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):378-85. PubMed ID: 12527051
[TBL] [Abstract][Full Text] [Related]
13. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S
J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658
[TBL] [Abstract][Full Text] [Related]
14. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy.
O'Donoghue J
Cancer Biother Radiopharm; 2004 Jun; 19(3):378-87. PubMed ID: 15285886
[TBL] [Abstract][Full Text] [Related]
15. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
DeNardo GL; Siantar CL; DeNardo SJ
Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
[TBL] [Abstract][Full Text] [Related]
16. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients?
Konijnenberg MW
Cancer Biother Radiopharm; 2003 Aug; 18(4):619-25. PubMed ID: 14503958
[TBL] [Abstract][Full Text] [Related]
17. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
18. Alternative models for estimating the radiotherapy retreatment dose for the spinal cord.
Jones B; Hopewell JW
Int J Radiat Biol; 2014 Sep; 90(9):731-41. PubMed ID: 24894515
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
20. [Biological aspects of radiation in nuclear medicine].
Kotzerke J; Oehme L
Nuklearmedizin; 2010; 49 Suppl 1():S5-S10. PubMed ID: 21152694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
